Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Journey Medical (DERM) EPS (Weighted Average and Diluted) (2020 - 2025)

Historic EPS (Weighted Average and Diluted) for Journey Medical (DERM) over the last 6 years, with Q3 2025 value amounting to -$0.09.

  • Journey Medical's EPS (Weighted Average and Diluted) rose 2500.0% to -$0.09 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.35, marking a year-over-year increase of 6276.6%. This contributed to the annual value of -$0.72 for FY2024, which is 24195.73% down from last year.
  • Latest data reveals that Journey Medical reported EPS (Weighted Average and Diluted) of -$0.09 as of Q3 2025, which was up 2500.0% from -$0.16 recorded in Q2 2025.
  • Journey Medical's 5-year EPS (Weighted Average and Diluted) high stood at $0.8 for Q3 2023, and its period low was -$1.89 during Q4 2021.
  • Moreover, its 5-year median value for EPS (Weighted Average and Diluted) was -$0.18 (2025), whereas its average is -$0.4.
  • Per our database at Business Quant, Journey Medical's EPS (Weighted Average and Diluted) plummeted by 92173.91% in 2021 and then soared by 24035.09% in 2023.
  • Quarter analysis of 5 years shows Journey Medical's EPS (Weighted Average and Diluted) stood at -$1.89 in 2021, then surged by 68.25% to -$0.6 in 2022, then skyrocketed by 80.0% to -$0.12 in 2023, then surged by 164.52% to $0.08 in 2024, then tumbled by 216.23% to -$0.09 in 2025.
  • Its EPS (Weighted Average and Diluted) stands at -$0.09 for Q3 2025, versus -$0.16 for Q2 2025 and -$0.18 for Q1 2025.